Rachel Cotton joined the T1D Fund in 2020. Recently, Rachel interned with MPM Capital, where she conducted due diligence on therapeutics opportunities for potential in-licensing, company creation, and Seed to Series A investments in oncology, cell and gene therapy, and autoimmunity. She also worked with new companies as a Project Manager with MassCONNECT, MassBio’s entrepreneur mentorship program.
Rachel received her Ph.D. in Immunology from Harvard University where she characterized a human T cell population recognizing a common self antigen in skin, and discovered agonists and antagonists of TCR recognition of this target antigen complex. She received her B.S. in Biological Sciences from the University of Notre Dame. Her research at Brigham and Women’s Hospital and Harvard Medical School, the National Institutes of Health, and the Notre Dame Eck Institute for Global Health has resulted in numerous publications.